Spironolactone TOPCAT Regional Analysis Falls Short At US FDA AdComm, But Hospitalizations Drive Vote

22 Dec 2020

A new indication for the generic diuretic in heart failure with preserved ejection fraction gets an 8-4 vote, with one abstention, despite troubles an analysis that tries to revive the TOPCAT trial with an analysis excluding Eastern European sites – or about half the participants.

top cat (shutterstock_160615241) — Advisory committee members found the secondary bowtie was more impressive than the top hat. • Source: Shutterstock

Spironolactone TOPCAT Regional Analysis Falls Short At US FDA AdComm, But Hospitalizations Drive Vote

More from US FDA Performance Tracker

More from Regulatory Trackers